Is Plasma Exchange Efficacious in Shiga Toxin‐Associated Hemolytic Uremic Syndrome? A Narrative Review of Current Evidence (original) (raw)
Treatment and outcome of Shiga-toxin-associated hemolytic uremic syndrome (HUS)
Sharon Andreoli
Pediatric Nephrology, 2008
View PDFchevron_right
Shiga Toxin–Associated Hemolytic Uremic Syndrome in Adults, France, 2009–2017
Sandrine Malot
2021
View PDFchevron_right
Severely ill pediatric patients with Shiga toxin-associated hemolytic uremic syndrome (STEC-HUS) who suffered from multiple organ involvement in the early stage
Mariana Luna
Pediatric Nephrology, 2020
View PDFchevron_right
Best supportive care and therapeutic plasma exchange with or without eculizumab in Shiga-toxin-producing E. coli O104:H4 induced haemolytic-uraemic syndrome: an analysis of the German STEC-HUS registry
Jan Kielstein
Nephrology Dialysis Transplantation, 2012
View PDFchevron_right
Clinical Features of Critically Ill Patients With Shiga Toxin–Induced Hemolytic Uremic Syndrome
Axel Nierhaus
Critical Care Medicine, 2013
View PDFchevron_right
Shiga toxin-associated hemolytic uremic syndrome
gökçe aşkın
Current Opinion in Nephrology and Hypertension, 2012
View PDFchevron_right
Shiga Toxin-Associated Hemolytic Uremic Syndrome and Unexpected Course (Shiga Toksin İlişkili Hemolitik Üremik Sendrom Tanılı Bir Olguda Beklenmedik Klinik Seyir)
Mehmet Fatih ORHAN
Turkish Nephrology Dialysis and Transplantation, 2012
View PDFchevron_right
Hemolytic Uremic Syndrome Caused by Shiga Toxin-Producing Escherichia coli Infections: An Overview
Imad Al-Sultan
Cloning & Transgenesis, 2014
View PDFchevron_right
Pathogenic role of inflammatory response during Shiga toxin-associated hemolytic uremic syndrome (HUS)
marina palermo
Pediatric nephrology (Berlin, Germany), 2018
View PDFchevron_right
Shiga Toxin-Mediated Hemolytic Uremic Syndrome: Time to Change the Diagnostic Paradigm?
Alexander Mellmann
PLoS ONE, 2007
View PDFchevron_right
Flow cytometry detection of Shiga toxins in the blood from children with hemolytic uremic syndrome
Francesca Ricci
Cytometry, 2004
View PDFchevron_right
Hemolytic uremic syndrome caused by Shiga toxin–producing Escherichia coli in children: incidence, risk factors, and clinical outcome
Harri Saxén
Pediatric Nephrology, 2020
View PDFchevron_right
Antibody Response to Shiga Toxins in Argentinean Children with Enteropathic Hemolytic Uremic Syndrome at Acute and Long-Term Follow-Up Periods
Ramon Exeni
PLoS ONE, 2011
View PDFchevron_right
Shiga Toxins Present in the Gut and in the Polymorphonuclear Leukocytes Circulating in the Blood of Children with Hemolytic-Uremic Syndrome
Maurizio Brigotti
Journal of Clinical Microbiology, 2006
View PDFchevron_right
Antibiotic treatment for infection with Shiga toxin producing Escherichia coli infection inducing a hemolytic uremic syndrome
Lars Lindberg
Trends Journal of Sciences Research
View PDFchevron_right
Safety and Pharmacokinetics of Chimeric Anti-Shiga Toxin 1 and Anti-Shiga Toxin 2 Monoclonal Antibodies in Healthy Volunteers
M. Riviere, M. Mehran
Antimicrobial Agents and Chemotherapy, 2009
View PDFchevron_right
The Hemolytic–Uremic Syndrome
P. Debourdeau
New England Journal of Medicine, 2002
View PDFchevron_right
An Atypical Case of Shiga Toxin Producing-Escherichia Coli Hemolytic and Uremic Syndrome (STEC-HUS) in a Lung Transplant Recipient
Diane Giovannini
Case Reports in Transplantation, 2019
View PDFchevron_right
Outbreak of Shiga toxin-producing Escherichia-coli-associated hemolytic uremic syndrome in Istanbul in 2015: outcome and experience with eculizumab
Mehmet Hanifi Tasdemir
Pediatric nephrology (Berlin, Germany), 2018
View PDFchevron_right
Severe Neurological Involvement in an Adult with Shiga Toxin-Producing <i>Escherichia coli</i>-Hemolytic Uremic Syndrome Treated with Eculizumab
Helene Georgery
Case reports in nephrology and dialysis, 2023
View PDFchevron_right
Hemolytic uremic syndrome in a developing country: Consensus guidelines
Arvind Bagga
Pediatric Nephrology, 2019
View PDFchevron_right
Eculizumab in Severe Shiga-Toxin–Associated HUS
Michael Kirschfink
New England Journal of Medicine, 2011
View PDFchevron_right
Severe Shiga Toxin Producing E. coli Hemolytic Uremic Syndrome in a Child with COVID-19
Fortune Journals
View PDFchevron_right
Effect of an Oral Shiga Toxin–Binding Agent on Diarrhea-Associated Hemolytic Uremic Syndrome in ChildrenA Randomized Controlled Trial
Howard Trachtman, Adrian Spitzer
JAMA, 2003
View PDFchevron_right
Hemolytic uremic syndrome: new developments in pathogenesis and treatment
Patrick Niaudet
International journal of nephrology, 2011
View PDFchevron_right
Induction of Neutrophil Extracellular Traps in Shiga Toxin-Associated Hemolytic Uremic Syndrome
Adriana Santiago
Journal of innate immunity, 2016
View PDFchevron_right
LPS-primed CD11b+ leukocytes serve as an effective carrier of Shiga toxin 2 to cause hemolytic uremic syndrome in mice
John Paluszynski
Scientific Reports, 2018
View PDFchevron_right
Unusual severe case of hemolytic uremic syndrome due to Shiga toxin 2d-producing E. coli O80:H2
Michiel Schreuder
Pediatric nephrology (Berlin, Germany), 2017
View PDFchevron_right
Shiga Toxin2 Induces Neutrophilia and Neutrophil Activation in a Murine Model of Hemolytic Uremic Syndrome
Gabriela Fernandez
Clinical Immunology, 2000
View PDFchevron_right
Predicting Hemolytic Uremic Syndrome and Renal Replacement Therapy in Shiga Toxin–producing Escherichia coli–infected Children
Ron Kaplan
Clinical Infectious Diseases
View PDFchevron_right